Application of CDCs (cardiosphere-derived cells) in biological material

A biomaterial and cell technology, applied in the application field of cardiac myosphere-derived cells in biomaterials, can solve the problems of impaired cardiac function, inability to reduce the mortality and morbidity of myocardial infarction, heart failure, heart failure, etc. , to achieve the effect of promoting activity, promoting stem cell proliferation and maintaining activity

Inactive Publication Date: 2018-06-22
广州沙艾生物科技有限公司
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although drug development and interventional therapy have made great progress, it is still unable to reduce the total mortality and morbidity of heart failure caused by myocardial infarction. Severe failure or malignant arrhythmia will eventually lead to the death of the patient; on the other hand, the intervention of drugs and interventional therapy makes a considerable number of patients with acute myocardial infarction survive, but the dead cells do not have new cells to replace their functions. During compensation, the function of the left ventricle and even the whole heart is severely damaged

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0038] S2. Preparation of platelet fibrin scaffold;

[0039] S3. Observation of platelet fibrin scaffold;

[0040] S4. Cardiac myospheric derived cells-platelet fibrin scaffold combined transplantation.

[0041] Preferably, the cultivation of cardiac myospheric-derived cells (CDCs) in the step S1 includes the following steps: take healthy clean-grade female 8-week-old WKY rat myocardial tissue, harvest the cells by tissue block culture method, and then culture them in suspension and (or) adherent culture to obtain rat cardiac myosphere-derived cells, observe cell morphology in vitro, observe cell activity by continuous passage, and draw cell growth curves; use flow cytometry to detect surface markers from different sources and different culture generations The expression of VEGF, IGF-1, SDF-1 and cells.

[0042] Preferably, the preparation of the platelet fibrin scaffold in step S2 also includes the following steps:

[0043] S1. Using isoflurane to deeply anesthetize the ra...

experiment example 1

[0060] Experimental example 1 in vivo experiment

[0061] (1) Experimental grouping and sampling time design

[0062] The first group (DMEM, i.e. conventional culture medium group) injected 100ulDMEM at the 3 o'clock, 6 o'clock, 9 o'clock and 12 o'clock positions around the infarcted myocardium of rats with acute myocardial infarction, totally 15;

[0063] The second group (platelet fibrin scaffold group) injected 100ul of dyed platelet fibrin scaffold at the 3 o'clock, 6 o'clock, 9 o'clock and 12 o'clock positions around the infarcted myocardium of rats with acute myocardial infarction, a total of 15 rats;

[0064] The third group (platelet fibrin scaffold+CDCs group) injected 100ul unstained platelet fibrin scaffold containing CDCs at the 3 o'clock, 6 o'clock, 9 o'clock and 12 o'clock positions around the infarcted myocardium of rats with acute myocardial infarction, a total of 15 rats.

[0065] The experimental sampling time points were the 12th hour, the 3rd day, the 7th ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention specifically discloses an application of CDCs (cardiosphere-derived cells) in a biological material. The application comprises following steps: S1, culture of CDCs; S2, preparation of aplatelet-rich fibrin stent; S3, observation of the platelet-rich fibrin stent; S4, combined transplantation of the CDCs-platelet-rich fibrin stent. The platelet-rich fibrin stent and CDCs can better correct the cardiac function after myocardial infarction; besides, the platelet-rich fibrin stent and the CDCs can promote each other, more vascular endothelial cells and cardiomyocytes can be regenerated after combined transplantation, the density of blood vessels in the infarction location can be increased, more stem cells can be collected to enter the infarction area to play a regeneration function, so that negative cardiac remodeling is reversed, and the cardiac function is improved.

Description

technical field [0001] The invention relates to the technical field of cardiac transplantation models, in particular to the application of cardiac myosphere-derived cells in biomaterials. Background technique [0002] Myocardial infarction and heart failure are one of the leading causes of human death in Western countries and have seriously increased the social and economic burden. Although drug development and interventional therapy have made great progress, it is still unable to reduce the total mortality and morbidity of heart failure caused by myocardial infarction. Severe failure or malignant arrhythmia will eventually lead to the death of the patient; on the other hand, the intervention of drugs and interventional therapy makes a considerable number of patients with acute myocardial infarction survive, but the dead cells do not have new cells to replace their functions. When compensating, the function of the left ventricle and even the whole heart is severely damaged....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L27/38A61L27/22
CPCA61L27/225A61L27/3826A61L27/3886A61L27/3895
Inventor 徐智峰张新
Owner 广州沙艾生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap